561 related articles for article (PubMed ID: 10207485)
21. Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer.
Kitajima K; Fukushima K; Miyoshi Y; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Maruyama K; Yamano T; Doi H; Yamakado K; Hirota S; Hirota S
Jpn J Radiol; 2016 Mar; 34(3):220-8. PubMed ID: 26715510
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous whole-body ¹⁸F-FDG PET-MRI in primary staging of breast cancer: a pilot study.
Taneja S; Jena A; Goel R; Sarin R; Kaul S
Eur J Radiol; 2014 Dec; 83(12):2231-2239. PubMed ID: 25282709
[TBL] [Abstract][Full Text] [Related]
23. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer.
Barranger E; Grahek D; Antoine M; Montravers F; Talbot JN; Uzan S
Ann Surg Oncol; 2003 Jul; 10(6):622-7. PubMed ID: 12839846
[TBL] [Abstract][Full Text] [Related]
25. FDG-PET/CT in the staging of local/regional metastases in breast cancer.
Robertson IJ; Hand F; Kell MR
Breast; 2011 Dec; 20(6):491-4. PubMed ID: 21807517
[TBL] [Abstract][Full Text] [Related]
26. Detection of pelvic lymph node metastases in gynecologic malignancy: a comparison of CT, MR imaging, and positron emission tomography.
Williams AD; Cousins C; Soutter WP; Mubashar M; Peters AM; Dina R; Fuchsel F; McIndoe GA; deSouza NM
AJR Am J Roentgenol; 2001 Aug; 177(2):343-8. PubMed ID: 11461859
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.
Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO
Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989
[TBL] [Abstract][Full Text] [Related]
28. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography.
Inoue T; Yutani K; Taguchi T; Tamaki Y; Shiba E; Noguchi S
J Cancer Res Clin Oncol; 2004 May; 130(5):273-8. PubMed ID: 14986112
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
Melsaether AN; Raad RA; Pujara AC; Ponzo FD; Pysarenko KM; Jhaveri K; Babb JS; Sigmund EE; Kim SG; Moy LA
Radiology; 2016 Oct; 281(1):193-202. PubMed ID: 27023002
[TBL] [Abstract][Full Text] [Related]
30. FDG/PET-CT-Based Lymph Node Atlas in Breast Cancer Patients.
Borm KJ; Voppichler J; Düsberg M; Oechsner M; Vag T; Weber W; Combs SE; Duma MN
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):574-582. PubMed ID: 30118822
[TBL] [Abstract][Full Text] [Related]
31. Fluorodeoxyglucose-PET in the management of breast cancer.
Kumar R; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1113-22, ix. PubMed ID: 15488561
[TBL] [Abstract][Full Text] [Related]
32. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas.
Bredella MA; Caputo GR; Steinbach LS
AJR Am J Roentgenol; 2002 Nov; 179(5):1145-50. PubMed ID: 12388489
[TBL] [Abstract][Full Text] [Related]
33. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
[TBL] [Abstract][Full Text] [Related]
34. Preoperative FDG-PET for axillary metastases in patients with breast cancer.
Chung A; Liou D; Karlan S; Waxman A; Fujimoto K; Hagiike M; Phillips EH
Arch Surg; 2006 Aug; 141(8):783-8; discussion 788-9. PubMed ID: 16924086
[TBL] [Abstract][Full Text] [Related]
35. Fluorine-18 FDG-PET in detecting local recurrence and distant metastases in breast cancer--Taiwanese experiences.
Lin WY; Tsai SC; Cheng KY; Yen RF; Kao CH
Cancer Invest; 2002; 20(5-6):725-9. PubMed ID: 12197228
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
Utech CI; Young CS; Winter PF
Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
[TBL] [Abstract][Full Text] [Related]
37. Comparison of 99mtechnetium-pertechnetate and 123iodide SPECT with FDG-PET in patients suspicious for breast cancer.
Buchmann I; Riedmüller K; Hoffner S; Mack U; Aulmann S; Haberkorn U
Cancer Biother Radiopharm; 2007 Dec; 22(6):779-89. PubMed ID: 18158769
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy of positron emission tomography and ultrasonography in preoperative evaluation of axillary lymph node metastases in breast cancer.
Ohta M; Tokuda Y; Saitoh Y; Suzuki Y; Okumura A; Kubota M; Makuuchi H; Tajima T; Yasuda S; Shohtsu A
Breast Cancer; 2000 Jan; 7(1):99-103. PubMed ID: 11029780
[TBL] [Abstract][Full Text] [Related]
39. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
[TBL] [Abstract][Full Text] [Related]
40. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases.
Ono K; Ochiai R; Yoshida T; Kitagawa M; Omagari J; Kobayashi H; Yamashita Y
J Magn Reson Imaging; 2009 Feb; 29(2):336-40. PubMed ID: 19161185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
